The investigational oral tyrosine kinase inhibitor (TKI) zongertinib showed promise in patients with previously treated HER2 ...

A group of cancer survivors and supporters from Western New York are traveling to Albany Tuesday to meet with state leaders ...

Small-cell lung cancer (SCLC) is one of the most aggressive and deadly types of cancer, often linked to smoking. Although it ...

Patients with previously treated non-small cell lung cancer (NSCLC) whose tumors harbored a KRAS G12D mutation experienced ...

A groundbreaking new urine test could soon help spot the early warning signs of lung cancer long before symptoms appear.

Overall, the one-time LDCT diagnostic performance in the non-risk-based screening population had a sensitivity of 96.6%, a ...

Li Qiang, director of the respiratory and critical care medicine department at the hospital, said the patient had over 10 ...

Raymond Osarogiagbon, MD, discusses the challenges of implementing lung cancer screening guidelines and the need for increased awareness and access.

Zongertinib, an oral therapy shown to have strong responses in patients previously treated for HER2 -mutated non–small cell ...

Non-small cell lung cancer (NSCLC) remains one of the leading causes of cancer-related deaths globally, and Ghana is no ...